FATE - Fate Therapeutics GAAP EPS of -$0.32 beats by $0.07, revenue of $1.63M beats by $0.45M
2025-05-13 17:54:36 ET
More on Fate Therapeutics
- Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
- Fate Therapeutics gets RMAT status from FDA for lupus treatment
- Seeking Alpha’s Quant Rating on Fate Therapeutics
- Historical earnings data for Fate Therapeutics
- Financial information for Fate Therapeutics